Compare RCUS & KFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RCUS | KFY |
|---|---|---|
| Founded | 2015 | 1969 |
| Country | United States | United States |
| Employees | 601 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Diversified Commercial Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.7B |
| IPO Year | 2018 | 1998 |
| Metric | RCUS | KFY |
|---|---|---|
| Price | $28.53 | $78.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | $31.90 | ★ $73.00 |
| AVG Volume (30 Days) | ★ 1.3M | 588.8K |
| Earning Date | 05-05-2026 | 06-17-2026 |
| Dividend Yield | N/A | ★ 2.90% |
| EPS Growth | N/A | ★ 13.48 |
| EPS | N/A | ★ 5.22 |
| Revenue | $247,000,000.00 | ★ $1,819,519,000.00 |
| Revenue This Year | N/A | $6.92 |
| Revenue Next Year | $45.62 | $3.25 |
| P/E Ratio | ★ N/A | $14.91 |
| Revenue Growth | N/A | ★ 12.20 |
| 52 Week Low | $8.84 | $58.27 |
| 52 Week High | $31.74 | $79.97 |
| Indicator | RCUS | KFY |
|---|---|---|
| Relative Strength Index (RSI) | 51.38 | 65.53 |
| Support Level | $20.20 | $66.27 |
| Resistance Level | $28.72 | $79.97 |
| Average True Range (ATR) | 1.33 | 1.83 |
| MACD | -0.16 | 0.44 |
| Stochastic Oscillator | 50.83 | 91.01 |
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Korn Ferry is a consulting firm that powers performance. The Company helps unlock the potential in people and unleash transformation across organizations synchronizing, operations, and talent to accelerate performance, fuel growth, and inspire a legacy of change. The company's segment includes Consulting, Digital, Executive Search North America, Executive Search EMEA, Executive Search APAC, Executive Search Latin America, Professional Search & Interim and RPO. The company generates the majority of its revenue from the Executive Search segment and Consulting segment. The Executive search segment helps organizations recruit board-level, chief executive, and other C-suite/senior executive and general management talent to deliver lasting impact.